Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORA | P35398 | 8/20 | 0.44 |
| ▸ | RORC | P51449 | 8/20 | 0.44 |
| ▸ | RORB | Q92753 | 8/20 | 0.44 |
| ▸ | PGR | P06401 | 7/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236096 | 0.96 | RORA (0.41) | RORARORCRORBPGRNR1H2 | |
| SCHEMBL5233756 | 0.90 | RORA (0.46) | RORARORCRORBPGRNR1H2 | |
| Hydrochloric Acid SCHEMBL5237070 | 0.89 | RORA (0.43) | RORARORCRORBPGRNR1H2 | |
| SCHEMBL5238978 | 0.87 | DPP4 (0.37) | RORARORCRORBPGRNR1H2 | |
| SCHEMBL5232664 | 0.86 | RORA (0.40) | RORARORCRORBPGRDPP4 | |
| SCHEMBL5239031 | 0.85 | RORA (0.44) | RORARORCRORBPGRNR1H2 | |
| SCHEMBL7009084 | 0.85 | RORA (0.41) | RORARORCRORBPGRNR1H2 | |
| SCHEMBL5238898 | 0.85 | LMNA (0.38) | RORARORCRORBPGRDPP4 | |
| SCHEMBL5233768 | 0.85 | DPP4 (0.37) | RORARORCRORBPGRDPP4 | |
| SCHEMBL5233506 | 0.85 | PGR (0.42) | RORARORCRORBPGRDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | RORA 2682/4885RORC 2671/4885RORB 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.